The stock of Abeona Therapeutics Inc (NASDAQ:ABEO) is a huge mover today! About 555,227 shares traded hands. Abeona Therapeutics Inc (NASDAQ:ABEO) has risen 178.20% since April 13, 2016 and is uptrending. It has outperformed by 174.27% the S&P500.
The move comes after 8 months negative chart setup for the $310.46M company. It was reported on Nov, 15 by Barchart.com. We have $6.06 PT which if reached, will make NASDAQ:ABEO worth $40.36M less.
Abeona Therapeutics Inc (NASDAQ:ABEO) Ratings Coverage
Out of 3 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Abeona Therapeutics has been the topic of 4 analyst reports since December 16, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Rodman & Renshaw on Wednesday, April 20. The stock of Abeona Therapeutics Inc (NASDAQ:ABEO) has “Buy” rating given on Wednesday, December 16 by Maxim Group. As per Thursday, September 29, the company rating was maintained by Maxim Group. As per Thursday, September 8, the company rating was initiated by Cantor Fitzgerald.
According to Zacks Investment Research, “Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States.”
More recent Abeona Therapeutics Inc (NASDAQ:ABEO) news were published by: Fool.com which released: “Why Abeona Therapeutics Inc. Is Surging Today” on October 18, 2016. Also Seekingalpha.com published the news titled: “Abeona Therapeutics: A Promising Gene Therapy Story” on October 10, 2016. Benzinga.com‘s news article titled: “263% Upside Seen In Abeona Therapeutics” with publication date: September 21, 2016 was also an interesting one.
ABEO Company Profile
Abeona Therapeutics, Inc. (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., incorporated on June 22, 1989, is focused on developing and delivering gene therapy and plasma products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV) gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. The Firm is also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD), and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a clustered, regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing approach to gene therapy program for rare blood diseases. In addition, it is developing rare plasma protein therapies, including PTB-101 SDF Alpha (alpha-1 protease inhibitor) for inherited chronic obstructive pulmonary disease (COPD) using its salt diafiltration (SDF) ethanol-free process. The Company’s product pipeline also consists of MuGard and ProdiGard.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.